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ABSTRACT. Chagas disease is a neglected tropical disease with 6-7 million people infected worldwide 
and there is no effective treatment. Therefore, there is an urgent need to continue researching in order to 
discover novel therapeutic alternatives. We present a series of arylaminoketone derivatives as means of 
identifying new drugs to treat Chagas disease in the acute phase with greater activity, less toxicity and 
with a larger spectrum of action than that corresponding to the reference drug benznidazole. Indexes of 
high selectivity found in vitro formed the basis for later in vivo assays in BALB/c mice. Murine model 
results show that compounds 3, 4, 7 and 10 induced a remarkable decrease in parasitemia levels in acute 
phase and the parasitemia reactivation following immunosuppression, and curative rates were higher 
  
 
than with benznidazole. These high anti-parasitic activities encourage us to propose these compounds as 
promising molecules for developing an easy to synthesize anti-Chagas agent. 
 
INTRODUCTION 
Chagas disease (CD), is caused by the protozoa Trypanosoma cruzi (T. cruzi) which is naturally 
transmitted by hematophagous insects, presents risk factors strongly linked to low socioeconomic 
factors and it is classified as a neglected tropical disease according to WHO.1, 2 CD is one of the most 
important medical problems in rural areas of the 21 endemic Latin America countries. Moreover, in the 
past decades migration and travelling have extended the spread of CD to other continents including 
North America,3 Europe4 and parts of the Western Pacific,5 where there is now a significant number of 
individuals with this disease. The worldwide incidence of CD has decreased thanks to the control 
programs; however, an estimated 6-7 million persons are infected worldwide.6 Approximately 20% of 
Latin American countries are endemic for this disease and up to 30-40% of patients will suffer chronic 
form of the disease in their lifetimes–i.e. important cardiac or digestive problems. 
Currently, the two drugs recommended for CD are benznidazole (BZN) and nifurtimox (NFX)7, 8 In 
general terms, BZN is the first line drug in most endemic countries9 because it is tolerated better but 
some of its secondary effects include dermatitis or neuropathy. Both drugs reduce parasitism during the 
acute and early CD stage, but drug efficacy during the chronic phase is limited. In addition, the efficacy 
of BNZ and NFX could change according to the geographical area, as consequence of a different 
susceptibility of the drugs by the different strains of T. cruzi.10 This background, including side effects 
and therapeutic deficiencies of these drugs, justifies the urgent need to continue researching in order to 
discover novel therapeutic alternatives. The ideal drug defined by its Target Product Profile (TPP) is 
outlined in Table 1. Briefly, it should present an efficacy at least equal to BZN and with a better safety 
profile. An oral drug in once-a-day in-house treatment for less than 30 days is desired and the new drug 
should be active against most parasite species.11-13   
  
 
Table 1. Proposed TPP for Chagas disease modified from DNDi.11  
Drug repositioning has emerged as one of the most fruitful strategies for improving and accelerating 
the drug development process. This strategy has become one of the most powerful tools for identifying 
compounds for the treatment of a disease different from the one they were originally designed for, used 
not only in the academic field but also in pharmaceutical companies. Different methods are considered 
under this strategy but 28 out of the 50 small molecules approved by the FDA between 1999 and 2008 
were discovered by phenotypic based drug design.14, 15 In this context we decided to screen our in-house 
chemical laboratory library with the purpose of searching drugs against of CD.16-21 We found some 
arylamine Mannich base derivatives tested before for their in vitro affinity at the 5-HT transporter and 
5HT1A receptors17 or 5-HT720 receptors as potential antidepressants and against Plasmodium falciparum 
as a potential antimalarials19 and in every case they were not active.  However risk of potential off-target 
activities derived from a possible CSN activity is unlikely.  
Herein we present the synthesis of arylaminoketone-type compounds and their in vitro evaluation 
against T. cruzi. Furthermore we show that the preliminary genotoxicity screening test revealed that this 
family of compounds is not genotoxic with or without metabolic activation, thereby providing the ideal 
chemical space for the development of new, potent and safe agents for the treatment of CD. High-
selectivity indexes and the genotoxicity screening have been the established cut-off to move into in vivo 
assays in BALB/c mice, where fresh blood examination was used to quantify the parasitemia. Also a 
cure was assayed by PCR, as was the reactivating of parasitemia in blood following 
immunosuppression. The mechanism of action has been explored at metabolic levels by 1H Magnetic 
Nuclear Resonance, and the study has been completed by testing their activity as potential Fe-
Superoxide dismutase inhibitors. Using computational approaches, we suggest a binding mode for the 
compounds to the enzyme. 
RESULTS AND DISCUSSION 
  
 
Chemistry. It is essential to identify the purpose of the synthesis of new small molecules. During the 
drug discovery process, mainly when facing NTD, the synthetic routes should allow the preparation of 
an important amount of different small molecules with a variety of substituents in order to explore and 
modify polarity, solubility, volume, rigidity and some other parameters that could influence activity and 
toxicity. Cost and commercial availability of chemicals should also be taken into consideration as well 
as the solvent and waste volumes. With these ideas in mind, the retrosynthetic analysis of the target 
compounds (1-20) suggested methylketones and arylamines as the appropriate building blocks (Table 
2). Compounds could be prepared in one step synthetic route with exception of compounds 10 and 13. 
In this case, both arylamines had to be prepared as previously reported.17, 20 The general method shown 
in Figure 1 was used to prepare the compounds presented in this work. The desired compounds were 
obtained condensing the adequate methylketone (commercially available) with the appropriate 
arylamine via Mannich reaction in acidic medium and using 1,3-dioxolane as the solvent and source of 
formaldehyde. 
Table 2. Relationship of synthesized compounds. 
Figure 1. General method of synthesis of new arylaminoketone derivatives. 
The results of the in silico study of some relevant molecular properties related to the drug-likeness of 
the compounds are shown in Table 3. It can be observed that none of them have a molecular weight 
higher than 500 g/mol, or an estimated partition coefficient (logP) higher than 5. Compounds 3, 6, 10, 
15 and 19 present a number of hydrogen-bond acceptors higher than 5 but lower than 10, while the 
number of donors is lower than 5 for all compounds. Therefore, all compounds fulfill the Lipinski “rule 
of five”. Finally, together with the acceptable partition coefficient values, the Polar Surface Area (PSA) 
of the compounds is lower than 140 Å2, and the aqueous solubility (logS) is similar or higher than -4, 
which anticipates good oral bioavailability. 
Table 3. Molecular properties of the new compounds calculated with the DataWarrior program.22 
  
 
In vitro Trypanocidal Evaluation. Information was gathered by the in vitro evaluation of activity of 
compounds 1-20 with respect to intra- and extracellular forms of T. cruzi SN3, Arequipa and Tulahuen 
strains obtained as detailed in the experimental section. Assays have been carried out in strains from 
different locations, hosts and tropisms, in order to determine if there are any differences in drug 
performance. 
Extracellular form (epimastigote) is the most commonly used owing to its easy culture in laboratory, 
but tests obtained on intracellular amastigotes (responsible for the chronic phase of CD) and blood 
trypomastigotes are more indicative due to these form of the parasite is the developed form in vertebrate 
hosts23. According to some authors, for deeming a compound as potential antichagasic agent, it has to 
meet certain criteria24. In the first place, the IC50 value has to be around 10 µM and the in second place 
the SI has to be 50 times higher than that of the reference drug. IC50 values for the 3 studied strains in 
both their extracellular and intracellular forms are shown in Table 4. 
Table 4 shows the IC50 values found at 72 h exposure using concentrations of 1-100 µM on assaying 
compounds 1-20 vs. 3 strains studied and the 3 forms of parasite cited above. The IC50 values for the 
drug BZN (reference) served for comparisons. Ten compounds (3, 4, 7, 10, 11, 13-15, 18 and 19) were 
shown to fulfill this first requisite. It was shown that the compounds meet this first requirement. Those 
compounds are the most active of the tested compounds for the three parasite forms assayed with an 
IC50 value lower than the one corresponding to the reference drug. 
 Table 4. In vitro activity and toxicity for the 20 arylaminoketone derivatives on extra- and 
intracellular forms of Trypanosoma cruzi strains. 
On the other hand, the cytotoxicity of compounds 1-20 was tested against Vero cells (Table 5) and a 
lesser cytotoxicity than the one of the reference drug was observed. Interestingly, toxicity data against 
Vero cells after 72 h of culture showed that all derivatives assayed were considerably less cytotoxic than 
drug reference BZN. Cytotoxicity IC50 values ranged from 30.1 µM to 2846.3 µM in sharp contrast with 
that obtained for BZN (13.6 µM). Only compounds 11 and 18 were more cytotoxic than BZN. 
  
 
Table 5. Selectivity index and in vitro toxicity for the 20 derivatives of arylaminoketone intra and 
extracellular of T .cruzi strains. 
In accordance with the above in vitro data, Table 5 presents the most notable selectivity index (SI) 
values, indicating in brackets how often the SI of each compound surpassed the SI of BNZ. This Table 
5 shows that excellent results were found for compounds 3, 4, 7 and 10 in all the parasite forms tested. 
Those drugs were chosen for further in vitro and in vivo assays and the possible mechanisms of action. 
In this case experiments were carried out only in the Arequipa strain as there are no significant 
differences between the performances of the compounds on the other studied strains.  
From a structural point of view, it can be said that the benzothiophene derivatives are less cytotoxic 
than the rest of the derivatives. All of the benzothiophene derivatives (1-10) present IC50 in Vero cells 
higher than 70 µM; moreover, the selected compounds (3, 4, 7, 10) present IC50 higher than 700 µM in 
contrast with BZN (13.6 µM). 
In vitro genotoxicity screening test. The potential genotoxicity of the compounds (1-5, 7, 10, 14, 16-
18) was screened using the SOS/umu test. The concentrations tested for each compounds were 
previously determined in a toxicity study in the test system. The SOS/umu screening test revealed that 
none of the tested compounds were genotoxic with or without metabolic activation. Meanwhile, both 
NFX and BZN were also tested and both of them were genotoxic in the tested conditions. The main 
purpose of including the SOS/umu test in the preliminary assays is to study the genotoxicity capacity of 
the most active compounds in vitro so that only compounds that are not genotoxic will move on to 
further studies. This test is convenient as a screening assay because it is a fast, simple and efficient 
method for testing the genotoxicity of a large number of samples. For these reasons, compounds 3, 4 
and 7, that had met the criteria for being moved on to in vivo models, were included in the SOS/umu 
test. Moreover, compounds 1, 2, 5, 10, 14 and 16-18 had been previously assayed in the genotoxicity 
screening test. These compounds came from our in-house chemical library and their in vitro 
trypanocidal activity had been studied, showing interesting results. Therefore and before synthesizing 
  
 
new related derivatives, we decided to explore their genotoxicity capacity to be sure that these new 
derivatives could be promising not only because of their potency but also because of their safeness. 
Both the trypanocidal activity and genotoxicity screening test mentioned above supported the idea of 
carrying out more detailed in vitro and in vivo assays with benzothiophenes 3, 4, 7 and 10 in order to get 
more information about their mode of action and their apparent advantages with respect to drug 
reference BZN. 
Infectivity assay. For fuller knowledge concerning the trypanocidal action of four compounds (3, 4, 7 
and 10), a subsequent determination was made of their impact on the intracellular replication and 
infectivity of amastigotes of T. cruzi (Figure 2). A sharp decline in the infection rate of the host cell 
occurred when the benzothiophene derivatives 3, 4, 7 and 10 were added to the infected Vero cells. 
Also, the four compounds proved to have greater effectiveness than did the reference drug, this reducing 
the infective capacity by 22% on day 10. (Figure 2A). Measuring of the mean number of amastigotes 
per infected Vero cell (Figure 2B) led to similar results: at the end of the treatment, the benzothiophene 
derivatives had decreased the number of amastigotes present in the cells by 45 to 74%, whereas BZN 
allowed only a poor reduction of 30%. With regard to the number of trypomastigote forms released in 
the medium (Figure 2C), on the whole, inhibition values were less significant. Even so, all the 
compounds showed a reduction by 47 to 68% and almost doubled the inhibitory effect of BZN (20%), 
which clearly remained less effective. Ultimately, infectivity tests confirmed the in vitro antiparasitic 
activity shown in Table 4 and 5 for the four compounds, and also their higher efficacy with respect to 
the reference drug. 
Figure 2. Reduction of the infection of Trypanosoma cruzi in Vero cells treated with (-■-) BZN, (-Δ-) 
3, (-□-) 4, (-●-) 7 and (-▲-) 10. (A) Rate of infection; (B) mean number of amastigotes per infected 
Vero cells; (C) number of trypomastigotes in the culture medium. Measured at IC25 .Values are the 
means of the three separate experiments. 
  
 
In Vivo Anti-T. cruzi Activity in BALB/c Albino Female Mice. Since compounds 3, 4, 7 and 10 
exhibited notable in vitro SI values in comparison to BZN (the reference drug) and the screening test 
showed no genotoxicity, those compounds were employed in more in vivo studies using BALB/c mice. 
Their ant-trypanosomal action prior to the acute CD phase to 40 days post-infection (pi) was studied 
first. Infection was imposed by intraperitoneal inoculation of metacyclic blood trypomastigotes (5x105) 
using Arequipa T. cruzi which results in lower mortality than do other approaches25, and compound 
doses of 50 and 100 mg/kg body weight were tested by oral administration on alternating days (7−15 
days pi). The parasites were counted in 5 µL blood samples taken from the mandibular vein. Notably, 
no mice died after receiving compounds 3, 4, 7 and 10. Figure 3 shows the effect caused by the 
benzothiophene derivatives on the parasitemia levels in blood during the acute phase of CD (day 0-40 
pi). (In Figure 3 only the results for the experiments performed with 100 mg/kg body weight dose are 
shown; not showing results for experiments with 50 mg/kg body weight dose, due to the evident 
majority effect of this first dose). A reduction of parasitemia in mice treated with the tested compounds 
was evident as soon as the very beginning of the treatment (day 7 pi), and it was maintained until the 
end of the acute phase (day 40 pi), and not only until the end of period of treatment (day 15 pi). In 
Figure 3 shows that mice treated with compounds 4 and 7, parasitemia was undetected in day 25 pi. 
This appears to indicate that parasites were eliminated, or their number depleted to non-detectable levels 
with a 100 dilution factor for counting in optic microscope, or maybe they migrated to organs. In the 
three detailed cases, they could no longer be detected in blood. 
Figure 3. Parasitemia in mice with acute CD. In (-♦-) control, (-▲-) BZN, (-●-) compound 3, (-■-) 
compound 4, (-Δ-) compound 7 and (-□-) compound 10. In all cases, compounds were orally 
administered using, for each compound, 100 mg/kg of body mass. Values constitute means of six mice 
± standard deviation. Treatment days are represented in grey. 
Performance of drugs during the chronic phase (where currently used drugs are not as effective as 
they should) was tested. 26,27 The parasitemia remaining in blood at day 90 pi is practically undetectable 
  
 
due to the parasite, in the amastigote form, is nested inside target organs. This involves that 
immunocompromised individuals cured with apparent success show high reactivation ability of the 
parasitemia. Furthermore, apparently cured patients submitted to liver or kidney transplantation, treated 
with anticancer chemotherapy or diagnosed with AIDS, showed clinically highly aggressive CD 
reactivation. As a means of providing information on this question, mice that were treated as indicated 
above, at 90 days pi received three successive immunosuppression cycles using cyclophosphamide 
monohydrate, as described above. 28 The aim was to reactivate the parasitemia, previously under the 
control of the immunological system of the mice. The tridimensional graph of Figure 4 shows the 
reactivation caused by compounds due to this reactivation is proportional to the survival rate of the 
parasites. Parasitemia reactivation reached 65% with respect to the acute phase in the control group of 
infected and untreated mice, whereas it decreased to 0% in the treated mice with 100 mg/kg body 
weight group revealing a significant effect on the chronic course of infection. Moreover, it can be 
observed that parasitemia reactivation decreased to 0% in mice treated with compound 7 not only with 
100 mg/kg but also with 50 mg/kg. 
Figure 4. Immunosuppression in vivo assay for mice untreated and treated with 100 mg/kg of body 
mass of BZN, 3, 4, 7 and 10. Figure shows the reactivation of blood parasitemia after the 
immunosuppression cycles by fresh blood containing parasitemia to the peak day during acute phase. 
ELISA (enzyme-linked immunosorbent assay) was employed to detect the total Ig-G levels using Fe-
SOD isolated by us as antigen source. An assessment of the immune status of the mice was made 
possible by the detection of total IgG, since this reflects the protection level that should be ascribed to 
the compounds tested, in combination with the animal’s natural protection. Results from the 
experiments using ELISA were verified using the parasitemia assay conducted as described above 
(Figure 5). The ELISA test indicated that the mice receiving compounds 3, 4, 7, and 10 maintained 
steady total IgG levels, as chronically infected mice also did; levels proved lower than in control after 
immunosuppression, whereas control levels rose following parasitemia reactivation. 
Figure 5. Shows differences in the IgG levels measured by ELISA at different day post-infection. 
  
 
Finally the curative effect of the compounds in the extracted target organs was evaluated. Figure 6 
only shows the PCR results of organs in the different groups of mice treated with 100 mg/kg body 
weight, because this dosage had better results. The controls showed the ubiquitous presence of the 
parasite in the 8 target organs. In addition, the figure shows the group of mice treated with BZN, in 
which 6 out of 8 target organs were infected. In contrast, the group of mice treated with the compounds 
3, 4, 7 and 10 showed less infected target organs than reference drug BZN, especially compounds 4 and 
7. Every organ of mice treated with drug 4 was not infected. In the case of compound 7, target organs 
were also not infected, while the two remaining target organs presented 83% less parasites than control.  
Cure assessment in chronic T. cruzi infection is controversial, mainly because of the lack of reliable 
tests to ensure parasite elimination.29 We should mention that identifying by PCR whether experimental 
animals have been cured is a critical question. This technique is able to detect a single parasite in 5 ml 
of blood and the main utility is to confirm failure to cure, because even consistently negative results 
cannot prove that tissue parasites have been completely eliminated.30, 31 Bioluminiscence imaging 
models techniques are being used currently to determinate if experimental animals have been cured. 
However, we can state that there are many evidences of cure (or, at least, a considerable reduction of the 
number of parasites), so the negative results of 5 independent samples by PCR and the absence of 
reactivation in blood after immunosuppression (double checking for demonstrating cure). 
Immunosupresion is the formula to demonstrate curation in all animal testing models, either 
bioluminescence-based tests or the ones that employ PCR as double checking ones.32 
The detection methodology has been improved significantly by specific PCR of genes and sequences 
with the development of the technology TaqMan, in the use of fluorogenic probes and the measurement 
of real-time amplification reaction used in the detection of sequences of constant regions and variables 
of minicircles of kinetoplast DNA. These results are quite useful to measure the parasitic load in chronic 
patients earlier and later after the treatment, and for the future establishment of reliable criteria of 
patient healing submitted to therapy .33 
  
 
Figure 6. Polymerase chain reaction (PCR) analysis of the 8 target organs on day 120 after infection. 
Lanes: M, base pair marker; 1: PCR negative control; 2: PCR positive control; 3: PCR adipose tissue; 4: 
PCR brain tissue; 5: PCR heart tissue; 6: PCR esophagus tissue; 7: PCR stomach tissue; 8: PCR bone 
marrow tissue; 9: PCR muscle tissue; 10: PCR lung tissue. * This means that 1/6 of the corresponding 
organ PCR products showed 300 bp band on electrophoresis. 
Finally, Table 6 shows weight percentage of spleens from different groups of mice in both doses of 
50 and 100 mg/kg body weight. Control group showed more weight percentage when compared with 
both groups of mice treated with 50 and 100 mg/kg body weight, which means that all compounds 
reduced splenomegaly and, therefore, infection rates. Moreover, groups of mice treated with 100 mg/kg 
body weight showed less weight percentage compared with the same groups of mice treated with a 
dosage of 50 mg/kg body weight. Compounds 3 and 7 showed lower splenomegaly. 
Table 6. Weight percent of spleens of different groups of mice. 
Inhibition of  the T. cruzi Fe-SOD Enzyme. The most studied therapeutic targets are enzymes, one 
of them is the trypanosomatid Fe-SOD, which presents structural and biochemical differences with 
respect to their human homologues. This enzyme plays a crucial role allowing the cell to avoid damage 
caused by the oxidative burst.34, 35 Taking this in account, we have given importance to iron superoxide 
dismutase (Fe-SOD), a trypanosomatid exclusive enzyme that is absent in other eukaryotic cells.36, 37 
Alternatively, trypanosomatids have a shared redox system in which trypanothione and glutathione team 
up to protect the parasite from reactive oxygen species (ROS). Trypanothione [bis(glutathionyl) 
spermidine] is synthesized from spermidine, the major polyamine in these parasites. Therefore, 
alterations in the biosynthesis of this amine can interfere in the defense mechanisms of the parasites 
against oxidative stress. Also noteworthy is the trypanothione synthase enzymes (trys) and 
trypanothione reductase (tryr), involved in the biosynthetic process trypanothione, which is the main 
defense system against oxidative trypanosomatids damage. The enzyme glutathione peroxidase 
constitutes the third block of main antioxidant enzymes of the parasite.38, 39  
  
 
As mentioned above, the antiparasitic activity of other benzothiophene derivatives partly accounted 
for by their inhibition of parasitic SOD. This could view as a possible target for designing new 
molecules capable of acting on metal ion carried within their structure.40-42  
As a means of gaining more evidence in this regard, the effects exerted on T. cruzi Arequipa strain Fe-
SOD by compounds 3, 4, 7 and 10 were assessed at concentrations of  between 1 µM to 100 µM.43 
Figure 7A shows the data on inhibition, and the related IC50 values appear in brackets. Figure 7B, for 
comparative purposes, presents the action of these same compounds regarding CuZn-SOD from human 
erythrocytes. Reflecting that the four compounds acted against Fe-SOD. Nevertheless Figure 7A 
indicates that the most trypanocidal compounds 3, 7 and 10 highly inhibited the enzyme activity, while 
the inhibitory activity of compound 4 was clearly lower. The graph shows that benzothiophene 3 
reached 100% inhibition of Fe-SOD at a 50 µM concentration and with an IC50 of 7.8 µM and that 
compounds 7 and 10 almost reached 100% inhibition at a slightly lower concentration, with IC50 values 
of 16.8 and 71.1 µM respectively. As the assay against FeSOD shows, compound 4 is the least efficient, 
as shown in its in vivo effects. However, it had curative effect in chronic phase. Some other mechanisms 
of action could be considered and the chance of a multi target compound should not be discarded. 
Figure 7. A) Inhibition in vitro (%) of Fe-SOD from epimastigotes of Trypanosoma cruzi for 
compounds (activity 25.4 ± 3.1 U/mg). B) Inhibition in vitro (%) of CuZn-SOD from human 
erythrocytes for compounds (activity 23.36± 2.5 U/mg). Activity differences in the control homogenate 
vs. the sample incubated using compounds were identified by the Newman-Keuls test. Values are the 
average of three separate rate determinations. 
Interestingly, the effect of compound 3 on human CuZn-SOD was substantially similar to the case of 
Fe-SOD (Figure 7A), since inhibitory activity scarcely reached 100% at the 50 µM concentration. The 
other three compounds (4, 7 and 10) did not show inhibition to CuZn-SOD, not even at 100 µM. These 
compounds are remarkable selective inhibitors of Fe-SOD. 
  
 
Metabolite excretion. Trypanosomatids proved incapable of completely degrade glucose to CO2, thus 
excreting into the medium part of their hexose skeleton as partly oxidized fragments. The percentage 
and  nature of this excretion depended on the pathway that was used in glucose metabolism.44 In T. 
cruzi, the catabolism product are mainly acetate, succinate, L-alanine and D-lactate.45  
In order to obtain some information about the effects of 3, 4, 7 and 10 on the glucose metabolism of 
the parasite, we registered the 1H NMR spectrum of T. cruzi epimastigotes treated with the test 
compounds (Supl information); the final excretion products were qualitatively and quantitatively 
identified. Figure 8 shows the results obtained and the comparison with control epimastigotes. 
Excretion of some metabolites, were disturbed in the treatment with the compounds, with the succinate 
being the most affected, and showing an increase of 199% for compound 10, 142% for compound 3, 22 
% for 4 and an increase of 109% for compound 7; lesser alterations were observed in the other 
metabolites. 
All of these data could be interpreted on the basis of a change in the succinate pathways occurring in 
the presence of the compounds under investigation. Otherwise, it is interesting to note that the increase 
in succinate with these compounds indicates catabolic changes that could be related to mitochondria 
malfunction, due to the redox stress produced by inhibition of the mitochondrion-resident Fe-SOD 
enzyme.46  
Figure 8. Percentages of variation among peaks of catabolites excreted by epimastigotes of  
Trypanosoma cruzi exposed to compounds 3, 4, 7 and 10 at their IC25 in comparison to a control 
incubated 96 h. 
Mutagenicity studies. Ames test  
Taking into account the great potential of compounds 4 and 7, we decided to include them in the 
Ames test to explore their mutagenicity capacity before considering them for further preclinical 
development. The results obtained from the Ames test for compound 4 and 7 are shown in Tables 7 and 
8, respectively. The evaluated doses of the compound were determined in a previous solubility study on 
  
 
the test system and 2.25 µg/plate and 0.75 µg/plate were established as the highest concentrations to be 
tested in the experimental conditions for compounds 4 and 7, respectively. No signs of cytotoxicity or 
precipitation were observed during the experiment. Both compounds were not mutagenic in any of the 
two tested conditions, as no evidence of dose-related or more than two-fold increase in the mean 
number or revertants was observed with or without metabolic activation. Therefore, compounds 4 and 7 
could be pointed as interesting candidates for the development of an anti-Chagas agent 
Table 7. Results of the Ames test of compound 4. 
Table 8. Results of the Ames test of compound 7. 
Docking study of benzothiophenes 3, 4, 7 and 10 in the T. cruzi Fe-SOD and the human CuZn-
SOD enzymes. 
In order to gain insight into the binding mode of the new benzothiophene derivatives in the Fe-SOD 
enzyme, docking studies were carried out using the crystal structure of both mitochondrial (PDB id 
4DVH) and cytosolic (PDB id 2GPC) Fe-SOD trypanothione cruzi proteins. The results showed that the 
compounds bind in a deep funnel at the top of the dimer interface, which gives access to the active site 
(metal site) (Figure 9a). This cavity has already been suggested as the inhibitor binding site.47 Even 
when the binding mode of the compounds in both enzymes was similar, the affinity was higher for the 
mitochondrial protein. However, we believe that this is merely an artifact produced by the different 
orientation of Lys36 (Lys35 in the mitochondrial enzyme), which lays inside the active site in the PDB 
2GPC and outside of it in PDB 4DVH. Based on our studies, we suggest the mitochondrial protein with 
PDB code 4DVH as best suited for docking studies on Fe-SOD trypanothione cruzi enzyme. The 
compounds bind in an aromatic pocket formed by aminoacids Try32, His28, Trp161 and Phe119. This 
hydrophobic pocket is flanked by polar residues at both sides: Glu162, Arg173, Val116 and Asn117 at 
one side, and Lys35 and Gln68 at the other. Just like the fluoro substituents of compounds 4 and 7, the 
nitro group of compounds 3 and 10 perform electrostatic interactions with Lys35, Gln68 and Asn117. 
As expected, the ligand does not perform interactions with the metal, which binds well inside the active 
  
 
site. However, it could act by inhibiting substrate access to the active site, or even by disrupting 
dimerization, as observed for other Fe-SOD inhibitors.48  
Docking studies of the four compounds on the human CuZn-SOD were also carried out in order to 
understand the reason for compound 3 presenting no selectivity, contrary to the other three compounds. 
Previous crystal structures show that organic fragments bind to this enzyme in different regions of its 
surface.49, 50 Our blind docking results coincide with this observation, no single binding site was found. 
However, for all four compounds, one of the two best scored poses presented the inhibitor bound on the 
dimer interface. This interface has already been suggested as the inhibitors binding site.51, 52 Therefore, 
we decided to perform another docking run defining this one as binding region. The results suggest a 
binding score around 10 times higher for compound 3 when compared with the other three compounds, 
coinciding with our experimental findings. Our docking results show compound 3 performing 
electrostatic interactions between the sulfur atom and Asp53, and between the nitro group and Lys9. 
Both interactions are absent in the other compounds (Figure 9b). 
Figure 9. Docking results for the binding of benzothiophenes 3 (up-left), 4 (down-left), 7 (up-right) and 
10 (down-right) to the Trypanosoma cruzi Fe-SOD (a) and the human CuZn-SOD (b) enzymes. In the 
center, an image of the entire enzyme with the compounds binding at the top of the dimer interface is 
shown. Residues forming the inhibitor binding site are shown. Color scheme: oxygen (red), nitrogen 
(blue), sulfur (yellow), carbon (pale pink for compound 3, orange for compound 4, blue for compound 7 
and magenta for compound 10. For the proteins, one monomer is shown in green and the other in 
yellow). The ions are shown as spheres. Figures were created with The PyMOL Molecular Graphics 
System, Version 1.8 Schrödinger, LLC. 
CONCLUSIONS 
In conclusion, of the 20 arylaminoketone derivatives tested, in vitro and in vivo experiments allowed 
us to identify 4 compounds (3, 4, 7 and 10) which showed improved trypanocidal properties and less 
toxicity. In addition, they present higher activity for treating Chagas disease during acute phase, higher 
  
 
curative rates and larger spectrum of action than the reference drug benznidazole. Moreover, none of the 
compounds included in the toxicological studies were genotoxic or mutagenic. Therefore, they are 
promising molecules for the development of an easy to synthesize anti-Chagas agent, and this allows us 
to think that these compounds could be immediately implemented into a step further within the 
preclinical phase. Finally, it merits mention that due to their different mechanisms of action, combined 
therapies should be considered for obtaining improved efficiency. 
EXPERIMENTAL SECTION 
CHEMISTRY 
General methods. All solvents and chemicals were used as purchased without further purification. 
Thin layer chromatography (TLC) using silica Alugram SIL G/UV254 (layer: 0.2 mm) (Macherey-
Nagel GmbH&Co. KG., Düren, Germany) and detection with UV light was used to monitor reactions. 
Conventional flash column chromatography was carried out with silica gel 60 (0.040_0.063 mm, 
Merck). Flash column chromatography was developed on a CombiFlash®Rf (TELEDYNE ISCO, 
Lincoln, USA) instrument with Silica RediSep®Rf columns. All of the synthesized compounds were 
chemically characterized by infrared (IR), proton nuclear magnetic resonance (1H NMR), carbon 
nuclear magnetic resonance (13C NMR) and elemental microanalyses (CHN). IR spectra were recorded 
on a Nicolet Nexus FTIR (Thermo, Madison, WI, U.S.) in KBr pellets. Data are reported as vibrational 
frequency (cm-1) and intensity is defined as strong (s), medium (m) and weak (w). In some cases, 2D 
NMR experiments (COSY, HMBC, HMQC) were carried out for the appropriate peaks assignment. 
NMR spectra were recorded in DMSO-d6 or CDCl3 solutions on a Bruker 400 Ultrashield instrument. 
The data are reported as follows: chemical shift in ppm from internal tetramethylsilane (TMS) standard 
on the δ scale, multiplicity (bs = broad singlet, s = singlet, d = doublet, dd = double doublet, ddd = 
double double doublet, t = triplet, m = multiplet) and coupling constants (J) values given in hertz (Hz). 
(See supporting information) All compounds were purified to ≥96% purity as determined by elemental 
microanalysis results obtained on a CHN-900 elemental analyzer (Leco, Tres Cantos, Spain) from 
vacuum-dried samples. The analytical results for C, H, and N were within ±0.4 of the theoretical values. 
  
 
Melting points (mp) were determined with a Mettler FP82 + FP80 apparatus (Greifensee, Switzerland) 
and are not corrected. 
Synthesis. Compounds 2, 3, 6, 10, 12 and 13 were previously reported.17-19  
General methodology for the preparation of arylamine Mannich base derivatives (1, 4, 5, 7-9, 
11, 14-20). A solution of the substituted methylketone (1.0 eq), the corresponding arylamine (1.0 eq), 
1,3-dioxolane (5 mL) and concentrated HCl (1 mL) was heated at reflux. The reaction was followed by 
TLC until conversion (30 min - 2 h). NaOH 2 M was added to basic pH and the product was extracted 
with CH2Cl2. The organic extracts were combined, dried over anhydrous Na2SO4, filtered and 
concentrated under reduced pressure. The residue was purified by column chromatography using 
CH2Cl2/methanol 95:5 (v/v) as mobile phase or Automated Flash Chromatography eluting in gradient 
with CH2Cl2/methanol 99:1 (v/v). The desired compounds were precipitated with diethyl ether. 
1-(benzo[b]thiophen-3-yl)-3-(4-(4-trifluoromethylphenyl)piperazin-1-yl)propan-1-one 
hydrochloride (1). Yield: 14%. mp: 209-210 ºC. IR (KBr) ν cm-1: 2552 (s, νHCl); 2458 (s, νHCl); 1660 (s, 
νC=O); 1335 (s, νC-F); 1166 (s, νC-F); 1113 (s, νC-F); 1073 (s, νC-F). 1H NMR (DMSO-d6, 400 MHz) δ ppm: 
11.45-11.26 (bs, 1H, HCl); 9.15(s, 1H, H2); 8.61 (d, 1H, H4, J4-5=7.9 Hz); 8.12 (d, 1H, H7, J7-6=7.8 Hz); 
7.57 (d, 2H, H3’+H5’, J3’-2’=8.7 Hz); 7.54-7.45 (m, 2H, H5+H6); 7.18 (d, 2H, H2’+H6’, J2’-3’=8.7 Hz); 
4.10-4.00 (m, 2H, 2Hp); 3.77 (t, 2H, CO-CH2, J=6.9 Hz); 3.72-3.62 (m, 2H, 2Hp); 3.55 (t, 2H, CH2-N, 
J=6.8 Hz); 3.34-3.19 (m, 4H, 2H2p+2H6p). 13C NMR (DMSO-d6, 100 MHz) δ ppm: 191.91; 151.97; 
140.51; 139.36; 135.99; 133.42; 125.89; 125.47; 124.51: 123.00; 114.91 (2C); 126.30 (2C, q, J3=4.0 
Hz); 124.78 (q, J1=268.0 Hz); 119.04 (q, J2=31.5 Hz); 50.52 (3C); 44.30 (2C); 34.01. Anal. calcd for 
C22H21F3N2OS.HCl: C 58.08%, H 4.87%, N 6.16%. Found: C 57.81%, H 4.80%, N 6.32%. 
1-(5-fluorobenzo[b]thiophen-3-yl)-3-(4-(4-trifluoromethylphenyl)piperazin-1-yl)propan-1-one 
(4). Yield: 26%. mp: 143-144 ºC. IR (KBr) ν cm-1: 1664 (s, νC=O); 1331 (s, νC-F); 1243 (s, νC-F); 1107 (s, 
νC-F). 1H NMR (CDCl3, 400 MHz) δ ppm: 8.48 (dd, 1H, H4, J4-F=10.3 Hz, J4-6=2.3 Hz); 8.40 (s, 1H, 
H2); 7.80 (dd, 1H, H7, J7-6=8.8 Hz, J7-F=4.8 Hz); 7.48 (d, 2H, H3’+H5’, J3’-2’=8.6 Hz); 7.20 (ddd, 1H, H6, 
J6-F=8.7 Hz, J6-7=8.7 Hz, J6-4=2.4 Hz); 6.92 (d, 2H, H2’+H6’, J2’-3’=8.6 Hz); 3.30-3.26 (m, 4H, 
  
 
2H3p+2H5p); 3.23 (t, 2H, CO-CH2, J=7.2 Hz); 2.94 (t, 2H, CH2-N, J=7.2 Hz); 2.72-2.68 (m, 4H, 
2H2p+2H6p). 13C NMR (CDCl3, 100 MHz) δ ppm: 193.73; 161.82 (d, J1=243.1 Hz); 153.20; 138.56; 
137.91 (d, J3=10.2 Hz); 134.87; 134.84; 126.37 (2C, q, J3=4.0 Hz); 124.72 (q, J1=270.1 Hz); 123.27 (d, 
J3=9.4 Hz); 120.55 (q, J2=32.6 Hz); 114.56 (d, J2=25.7 Hz); 114.52 (2C); 111.62 (d, J2=25.2 Hz); 53.13; 
52.98 (2C); 47.98 (2C); 37.81. Anal. calcd for C22H20F4N2OS: C 60.54%, H 4.62%, N 6.42%. Found: C 
60.37%, H 4.30%, N 6.39%. 
1-(5-fluorobenzo[b]thiophen-3-yl)-3-(4-(4-chlorophenyl)piperazin-1-yl)propan-1-one (5). Yield: 
33%. mp: 156-157 ºC. IR (KBr) ν cm-1: 1660 (s, νC=O); 1246 (s, νC-F).1H NMR (DMSO-d6, 400 MHz) δ 
ppm: 9.17 (s, 1H, H2); 8.32 (dd, 1H, H4, J4-F=10.6 Hz, J4-6=2.6 Hz); 8.15 (dd, 1H, H7, J7-6=8.8 Hz, J7-
F=5.2 Hz); 7.88 (ddd, 1H, H6, J6-F=9.0 Hz, J6-7=8.9 Hz, J6-4=2.8 Hz); 7.21 (d, 2H, H3’+H5’, J3’-2’=9.2 
Hz); 6.93 (d, 2H, H2’+H6’, J2’-3’=9.2 Hz); 3.27 (t, 2H, CO-CH2, J=7.0 Hz); 3.14-3.07 (m, 4H, 
2H3p+2H5p); 2.80 (t, 2H, CH2-N, J=7.2 Hz); 2.62-2.54 (m, 4H, 2H2p+2H6p). 13C NMR (DMSO-d6, 100 
MHz) δ ppm: 212.89; 160.96 (d, J1=240.8 Hz); 149.56; 142.13; 137.43 (d, J3=10.5 Hz); 135.06 (d, 
J4=1.3 Hz); 133.64 (d, J4=4.5 Hz); 128.46 (2C); 124.57 (d, J3=9.7 Hz); 122.24; 116.70 (2C); 113.90 (d, 
J2=25.2 Hz); 109.96 (d, J2=24.9 Hz); 52.64; 52.30 (2C); 47.72 (2C); 36.91. Anal. Calcd. for 
C21H20ClFN2OS: C 62.60%, H 5.00%, N 6.95%. Found: C 62.23%, H 4.63%, N 6.87%. 
1-(5-fluorobenzo[b]thiophen-3-yl)-3-(4-(4-fluorophenyl)piperazin-1-yl)propan-1-one (7). Yield: 
18%. mp: 156-157 ºC. IR (KBr) ν cm-1: 1661 (s, νC=O); 1175 (s, νC-F); 1131 (s, νC-F). 1H NMR (CDCl3, 
400 MHz) δ ppm: 8.48 (dd, 1H, H4, J4-F=10.4 Hz, J4-6= 2.6 Hz); 8.39 (s, 1H, H2); 7.79 (dd, 1H, H7, J7-
6=8.8 Hz, J7-F=4.8 Hz); 7.19 (ddd, 1H, H6, J6-F=8.6 Hz, J6-7=8.6 Hz, J6-4=2.5 Hz); 6.99-6.93 (m, 2H, 
H3’+H5’); 6.89-6.84 (m, 2H, H2’+H6’); 3.22 (t, 2H, CO-CH2, J=7.3 Hz); 3.14-3.11 (m, 4H, 2H3p+2H5p); 
2.94 (t, 2H, CH2-N, J=7.3 Hz); 2.71-2.68 (m, 4H, 2H2p+2H6p). 13C NMR (CDCl3, 100 MHz) δ ppm: 
193.82; 161.78 (d, J1=243.8 Hz); 157.15 (d, J1=239.9 Hz); 147.86 (d, J4=2.2 Hz); 138.56; 137.89 (d, 
J3=10.7 Hz); 135.11 (d, J4=1.6 Hz); 134.84 (d, J4=4.5 Hz); 123.23 (d, J3=9.5 Hz); 117.80 (2C, d, J3=7.6 
Hz); 115.48 (2C, d, J2=22.0 Hz); 114.51 (d, J2=25.6 Hz); 111.60 (d, J2=25.2 Hz); 53.26 (2C); 53.15; 
  
 
50.14 (2C); 37.81. Anal. Calcd. for C21H20F2N2OS: C 65.27%, H 5.22%, N 7.25%. Found: C 64.94%, H 
5.18%, N 6.88%. 
1-(benzo[b]thiophen-3-yl)-3-(4-benzylpiperazin-1-yl)propan-1-one hydrochloride (8). Yield: 
12%. mp: 202-203 ºC. IR (KBr) ν cm-1: 2515 (m, νHCl); 2406 (m, νHCl); 1664 (s, νC=O). 1H NMR 
(DMSO-d6, 400 MHz) δ ppm: 11.93 (s, 2H, HCl); 9.04 (s, 1H, H2); 8.60 (d, 1H, H4, J4-5=7.9 Hz); 7.11 
(d, 1H, H7, J7-6=7.6 Hz); 7.71-7.57 (m, 2H, H5+H6); 7.56-7.36 (m, 5H, H2’-H6’); 4.36 (s, 2H, CH2-benzyl); 
3.84-3.66 (m, 6H, CO-CH2+2H3p+2H5p); 3.66-3.19 (m, 6H, CH2-N+2H2p+2H6p). 13C NMR (DMSO-d6, 
100 MHz) δ ppm:. 181.92; 161.21; 150.86; 140.51; 139.36; 135.99; 128.75; 125.87 (2C); 125.47 (2C); 
124.98; 124.52 (2C); 123.00; 73.22; 57.70 (3C); 47.33 (2C); 36.99. Anal. Calcd. for C22H24N2OS.2HCl: 
C 60.41%, H 5.99%, N 6.40%. Found: C 60.02%, H 6.08%, N 6.27%. 
1-(benzo[b]thiophen-3-yl)-3-(4-(3-fluorobenzyl)piperazin-1-yl)propan-1-one hydrochloride (9). 
Yield: 12%. mp: 214-215 ºC. IR (KBr) ν cm-1: 2525 (m, νHCl); 2449 (m, νHCl); 1668 (s, νC=O). 1H NMR 
(DMSO-d6, 400 MHz) δ ppm: 11.45-11.26 (bs, 2H, HCl); 9.05(s, 1H, H2); 8.61 (d, 1H, H4, J4-5=7.7 
Hz); 8.12 (d, 1H, H7, J7-6=7.8 Hz); 7.66-62 (m, 2H, H5+H6); 7.57-7.52 (m, 4H, H2’+H4’+H5’+H6’); 4.41 
(s, 2H, CH2-benzyl); 3.85-3.65 (m, 12H, 8Hp+COCH2+CH2N). Anal. Calcd. for C22H23FN2OS.2HCl: C 
58.02%, H 5.53%, N 6.15%. Found: C 58.40%, H 5.71%, N 6.00%. 
1-(thiophen-3-yl)-3-(4-(3-trifluoromethylphenyl)piperazin-1-yl)propan-1-one hydrochloride 
(11). Yield: 18%. mp: 177-178 ºC. IR (KBr) ν cm-1: 2459 (m, νHCl); 1682 (s, νC=O); 1166 (s, νC-F); 1120 
(s, νC-F); 1076 (s, νC-F). 1H NMR (DMSO-d6, 400 MHz) δ ppm: 11.45-11.28 (bs, 1H, HCl); 8.61 (s, 1H, 
H2); 7.68 (dd, 1H, H5, J5-4=4.6 Hz, J5-2=2.5 Hz); 7.55 (d, 1H, H4, J4-5=5.0 Hz); 7.47 (t, 1H, H5’, J5-4’=7.9 
Hz); 7.37-7.24 (m, 2H, H2’+H6’); 7.16 (d, 1H, H4’, J4’-5’=7.3 Hz); 4.04-3.93 (m, 2H, CO-CH2); 3.70-
3.57 (m, 4H, 2H3p+2H5p); 3.52-3.43 (m, 2H, CH2-N); 3.28-3.14 (m, 4H, 2H2p+2H6p). 13C NMR 
(DMSO-d6, 100 MHz) δ ppm: 190.90; 149.84; 141.07; 134.29; 130.10; 129.92 (q, J2=30.7 Hz); 127.76; 
126.32; 124.28 (q, J1=272.0 Hz); 119.22; 115.65 (q, J3=3.6 Hz); 111.03 (q, J3=3.5 Hz); 50.57 (2C); 
50.35; 44.86 (2C); 33.73. Anal. Calcd. for C18H19F3N2OS.HCl: C 53.40%, H 4.98%, N 6.92%. Found: C 
53.02%, H 5.02%, N 6.85%. 
  
 
1-(naphthalen-2-yl)-3-(4-(4-trifluoromethylphenyl)piperazin-1-yl)-propan-1-one (14). Yield: 
66%. mp: 150-151 ºC. IR (KBr) ν cm-1: 1677 (s, νC=O); 1148 (s, νC-F); 1098 (s, νC-F); 1065 (s, νC-F). 1H 
NMR (DMSO-d6, 400 MHz) δ ppm: 8.72 (s, 1H, H1); 8.14 (d, 1H, H8, J8-7=7.7 Hz); 8.03-7.97 (m, 3H, 
H3-H5); 7.69-7.59 (m, 2H, H6+H7); 7.48 (d, 2H, H3’+H5’, J3’-2’=8.8 Hz); 7.04 (d, 2H, H2’+H6’, J2’-3’=8.8 
Hz); 3.37 (t, 2H, CO-CH2, J=7.2 Hz); 3.27-3.21 (m, 4H, 2H3p+2H5p); 2.79 (t, 2H, CH2-N, J=7.2 Hz); 
2.61-2.55 (m, 4H, 2H2p+2H6p). 13C NMR (DMSO-d6, 100 MHz) δ ppm: 199.19; 153.24; 135.03; 
134.00; 132.23; 129.95; 129.60; 128.61; 128.26; 127.64; 126.91; 126.13 (2C, q, J3=3.8 Hz); 124.99 (q, 
J1=270.1 Hz); 123.55; 117.78 (q, J2=32.0 Hz); 114.12 (2C); 52.92; 52.41 (2C); 46.96 (2C); 35.81. Anal. 
Calcd. for C24H23F3N2O: C 69.89%, H 5.62%, N 6.79%. Found: C 69.82%, H 5.72%, N 6.76%. 
1-(naphthalen-2-yl)-3-(4-(4-nitrophenyl)piperazin-1-yl)-propan-1-one (15). Yield: 86%. mp: 190-
191 ºC. IR (KBr) ν cm-1: 2806 (s, νC-H); 1674 (s, νC=O). 1H NMR (DMSO-d6, 400 MHz) δ ppm: 8.74 (s, 
1H, H1); 8.14 (d, 1H, H8, J8-7=7.8 Hz); 8.04 (m, d, 2H, H3’+H5’, J3’-2’=9.4 Hz); 8.02-7.98 (m, 3H, H3-
H5); 7.70-7.60 (m, 2H, H6+H7); 7.03 (d, 2H, H2’+H6’, J2’-3’=9.4 Hz); 3.48-3.42 (m, 4H, 2H3p+2H5p); 
3.40 (t, 2H, COCH2, J=7.2 Hz); 2.80 (t, 2H, CH2-N, J=7.2 Hz); 2.62-2.56 (m, 4H, 2H2p+2H6p). 13C 
NMR (DMSO-d6, 100 MHz) δ ppm: 199.07; 154.68; 136.75; 134.98; 133.92; 132.19; 129.94; 129.56; 
128.57; 128.20; 127.60; 126.86; 125.66 (2C); 123.50; 112.55 (2C); 52.75; 52.24 (2C); 46.23 (2C); 
35.71. Anal. Calcd. for C23H23N3O3: C 70.93%, H 5.95%, N 10.79%. Found: C 70.99%, H 5.85%, N 
10.58%. 
3-(4-(4-fluorophenyl)piperazin-1-yl)-1-(naphthalen-2-yl) propan-1-one (16). Yield: 15%. mp: 98-
99 ºC. IR (KBr) ν cm-1: 2800 (m, νC-H); 1676 (s, νC=O); 1177 (s, νarC-F); 1134 (s, νarC-F). 1H NMR (CDCl3, 
400 MHz) δ ppm: 8.50 (s, 1H, H1); 8.04 (dd, 1H, H8, J8-7=8.6 Hz, J8-6=1.7 Hz); 7.97 (d, 1H, H3, J3-4=8.0 
Hz); 7.91 (d, 1H, H5, J5-6=8.8 Hz); 7.88 (d, 1H, H4, J4-3=8.7 Hz); 7.64-7.54 (m, 2H, H6+H7); 6.97 (dd, 
2H, H3’+H5’, J3’-2’=9.0 Hz, J3’-F=8.4 Hz); 6.88 (dd, 2H, H2’+H6’, J2’-3’=9.2 Hz, J2’-F=4.6 Hz); 3.37 (t, 2H, 
CO-CH2, J=7.4 Hz); 3.17-3.12 (m, 4H, 2H3p+2H5p); 2.97 (t, 2H, CH2-N, J=7.4 Hz); 2.75-2.70 (m, 4H, 
2H2p+2H6p). 13C NMR (CDCl3, 100 MHz) δ ppm: 198.93; 159.17 (d, J1=239.1 Hz); 147.89 (d, J4= 2.2 
Hz); 135.60; 134.22; 132.51; 129.71; 129.54; 128.51 (2C); 127.77; 126.81; 123.78; 117.82 (2C, d, 
  
 
J3=7.9 Hz); 115.48 (2C, d, J2=22.1 Hz); 53.28 (2C); 53.25; 50.14 (2C); 36.33. Anal. Calcd. for 
C23H23FN2O: C 76.22%, H 6.40%, N 7.73%. Found: C 76.46%, H 6.57%, N 7.60%. 
1-(benzo[d][1,3]dioxol-5-yl)-3-(4-(4-trifluoromethylphenyl)piperazin-1-yl)propan-1-one (17). 
Yield: 21%. mp: 107-108 ºC. IR (KBr) ν cm-1: 1669 (s, νC=O); 1158 (s, νC-F); 1111 (s, νC-F); 1072 (s, νC-
F). 1H NMR (DMSO-d6, 400 MHz) δ ppm: 7.65 (1H, d, H6, J6-7=8.2 Hz); 7.48 (d, 2H, H3’+H5’, J3’-2’=8.4 
Hz); 7.47 (s, 1H, H4); 7.04 (dd, 3H, H2’+H6’+H7, J2’-3’=J7-6=8.7 Hz); 6.13 (s, 2H, 2H2); 3.28-3.2 (m, 4H, 
2H3p+2H5p); 3.16 (t, 2H, CO-CH2, J=7.1 Hz); 2.70 (t, 2H, CH2-N, J=7.1 Hz); 2.59-2.52 (m, 4H, 
2H2p+2H6p). 13C NMR (DMSO-d6, 100 MHz) δ ppm: 197.06; 153.16; 151.28; 147.71; 131.35; 126.01 
(2C, q, J3=3.7 Hz); 124.91 (q, J1=270.5 Hz); 124.28; 117.66 (q, J2=32.0 Hz); 114.01 (2C); 107.92; 
107.33; 101.89; 52.89; 52.29 (2C); 46.85 (2C); 35.45. Anal. Calcd. for C21H21F3N2O3: C 62.06%, H 
5.21%, N 6.89%. Found: C 62.06%, H 5.60%, N 7.03%. 
1-(benzo[d][1,3]dioxol-5-yl)-3-(4-(4-chlorophenyl)piperazin-1-yl)propan-1-one (18). Yield: 20%. 
mp: 105-106 ºC. IR (KBr) ν cm-1: 1675 (s, νC=O); 1241 (s, νC-O). 1H NMR (DMSO-d6, 400 MHz) δ ppm: 
7.64 (dd, 1H, H6, J6-7=8.2 Hz, J6-4=1.3 Hz); 7.46 (s, 1H, H4); 7.20 (d, 2H, H3’+H5’, J3’-2’=8.9 Hz); 7.02 
(d, 1H, H7, J7-6=8.2 Hz); 6.92 (d, 2H, H2’+H6’, J2’-3’=8.9 Hz); 6.12 (s, 2H, 2H2); 3.14 (t, 2H, CO-CH2, 
J=7.1 Hz); 3.11-3.05 (m, 4H, 2H3p+2H5p); 2.69 (t, 2H, CH2-N, J=7.1 Hz); 2.57-2.51 (m, 4H, 
2H2p+2H6p). 13C NMR (DMSO-d6, 100 MHz) δ ppm: 197.20; 151.35; 149.78; 147.78; 131.40; 128.55 
(2C); 124.38; 122.22; 116.74 (2C); 108.00; 107.38; 101.97; 52.98; 52.49 (2C); 47.95 (2C); 35.52. Anal. 
Calcd. for C20H21ClN2O3: C 64.43%, H 5.68%, N 7.51%. Found: C 64.61%, H 5.86%, N 7.40%. 
1-(benzo[d][1,3]dioxol-5-yl)-3-(4-(4-nitrophenyl)piperazin-1-yl)propan-1-one (19). Yield: 50%. 
mp: 164-165 ºC. IR (KBr) ν cm-1: 1665 (s, νC=O); 1241 (s, νC-O). 1H NMR (DMSO-d6, 400 MHz) δ ppm: 
8.04 (d, 2H, H3’+H5’, J3’-2’=9.4 Hz); 7.65 (dd, 1H, H6, J6-7=8.2 Hz, J6-4=1.4 Hz); 7.47 (s, 1H, H4); 7.06-
7.00 (m, 3H, H7+H2’+H6’); 6.13 (s, 2H, 2H2); 3.46-3.40 (m, 4H, 2H3p+2H5p); 3.16 (t, 2H, CO-CH2, 
J=7.0 Hz); 2.70 (t, 2H, CH2-N, J=7.1 Hz); 2.57-2.51 (m, 4H, 2H2p+2H6p). 13C NMR (DMSO-d6, 100 
MHz) δ ppm: 197.08; 154.66; 151.33; 147.75; 136.75; 131.35; 125.64 (2C); 124.35; 112.54 (2C); 
  
 
107.98; 107.38; 101.94; 52.78; 52.17 (2C); 46.21 (2C); 35.42. Anal. Calcd. for C20H21N3O5: C 62.65%, 
H 5.52%, N 10.96%. Found: C 62.29%, H 5.43%, N 10.61%. 
1-(benzo[d][1,3]dioxol-5-yl)-3-(4-(4-fluorophenyl)piperazin-1-yl)propan-1-one (20). Yield: 19%. 
mp: 96-97 ºC. IR (KBr) ν cm-1: 1676 (s, νC=O); 1242 (s, νC-O). 1132 (s, νC-F); 1109 (s, νC-F). 1H NMR 
(DMSO-d6, 400 MHz) δ ppm: 7.65 (d, 1H, H6, J6-7=8.0 Hz); 7.47 (s, 1H, H4); 7.07-6.99 (m, 3H, 
H3’+H5’+H7); 6.93 (dd, 2H, H2’+H6’, J2’-3’=8.9 Hz, J2’-F=4.6 Hz); 6.13 (s, 2H, 2H2); 3.14 (t, 2H, CO-
CH2, J=7.0 Hz); 3.08-2.99 (m, 4H, 2H3p+2H5p); 2.69 (t, 2H, CH2-N, J=7.1 Hz); 2.59-2.52 (m, 4H, 
2H2p+2H6p). 13C NMR (DMSO-d6, 100 MHz) δ ppm: 197.10; 155.84 (d, J1=235.4 Hz); 151.26; 147.82 
(d, J4=1.9 Hz); 147.71; 131.35; 124.28; 116.92 (2C, d, J3=7.5 Hz); 115.10 (2C, d, J2=21.8 Hz); 107.92; 
107.32; 101.89; 52.94; 52.59 (2C); 48.85 (2C); 35.49. Anal. Calcd. for C20H21FN2O3: C 67.40%, H 
5.94%, N 7.86%. Found: C 67.30%, H 6.04%, N 7.75%. 
Calculation of molecular properties. The drug-likeness of the compounds was estimated with 
Osiris, using the stand-alone DataWarrior program.22 The information about the methods used to 
evaluate each property is available on the program web site http://www.openmolecules.org. 
BIOLOGY 
In vitro Trypanocidal Evaluation 
Parasite strain culture. Epimastigote and trypomastigote forms: Epimastigote assays. The 
epimastigote forms of T. cruzi SN3 strain (IRHOD/CO/2008/SN3, DTU I) that were isolated from the 
household triatomine Rhodnius prolixus (from Guajira, Colombia).53 Epimastigotes of T. cruzi Arequipa 
strain (MHOM/Pe/2011/ Arequipa, DTU V) isolated from a human and Tulahuen strain 
(TINF/CH/1956/Tulahuen, DTU VI) were cultivated in vitro using trypanosome liquid medium (MTL) 
containing 10% inactivated fetal bovine serum and maintained at 28°C in an air atmosphere, in Roux 
flasks (Corning, USA) of 75 cm2 surface area, as described in previous studies.54 The epimastigote 
forms transformed into metacyclic forms by metacyclogenesis triggered by culturing a 5-day-old  
epimastigote forms that had been harvested by centrifuging (7000 g) at 10 ºC for 10 min. Next the 
parasites were incubated at 28 ºC for 2 h (density of 5 x 108 cells/mL) in TAU medium (190 mM NaCl, 
  
 
17 mM KCl, 2 mM MgCl2, 2 mM CaCl2, 8 mM phosphate buffer, pH 6.0). The parasites were then 
incubated at a dilution of 1:100 (final concentration of epimastigotes: 5 × 106 cells/mL) at 28 ºC f or 96 
h in TAU3AAG medium (TAU supplemented with 10 mM L-proline, 50 mM L-sodium glutamate, 2 
mM L-sodium aspartate and 10 mM D-glucose) in 25 mL flasks with a layer culture medium no more 
than 1 cm in deep.55 
Trypomastigote Forms assays. The activity (parasite-reduction %) was compared to control with the 
method described above54, with certain modifications in our lab. The test of drug action against T. cruzi 
used Balb/c albino mouse blood collected during peak parasitemia (day 7). The infected blood was 
diluted using uninfected mouse blood at a concentration of 4 x 106 trypomastigotes/mL. Then, in RPMI 
1640 medium-GIBCO (2 x 106 trypomastigotes/mL), a dilution was made to 1:2. Stock solutions of the 
compounds were prepared in DMSO. The IC50 values were calculated using, samples of infected blood, 
adding each drug to wells in a 96-microwell plate for a final 200 µL volume for drug concentrations of 
1, 10, 25, 50, and 100 µM., and the plates were then incubated for 24 h at 4- to 8 ºC. Each experiment 
was replicated three times (OLYMPUS CX41) and the parasites were counted in the Neubauer chamber. 
Cytotoxicity and Cell Culture Tests. Vero cells (EACC number 84113001) originally extracted from 
monkey kidney, were cultured for two days in RPMI (Gibco), supplemented with 10% inactivated fetal 
bovine serum in 95% humidified air, 5% CO2 at 37 ºC. The cytotoxicity test was performed for Vero 
cells following a methodology described previously.54 Flow cytometry was used to determine cell 
viability after 72 h of treatment. Propidium iodide solution (100 mg/mL) was added at 100 μL/well and 
incubated at 28 °C for 10 min in darkness. Then, fluorescein diacetate (100 ng/mL) was added at 100 
μL/well and incubated using the same conditions. The cells were collected by centrifuging (400 g for 10 
min), and finally the precipitate was washed using PBS (phosphate buffered saline). Flow cytometry 
was performed with a FACSVantage flow cytometer (Becton Dickinson), and the percentage of viability 
was computed in comparison to control. The IC50 was calculated with linear-regression analysis 
employing the Kc values corresponding to the concentrations used (0.1 to 100 μM). 
  
 
In Vitro Activity. Epimastigote Forms Assays (Extracellular Forms). The compounds obtained and 
BZN (the reference drug), dissolved in DMSO (Panreac, Barcelona, Spain) at a 0.01% (v/v) 
concentration and assayed, proved nontoxic to the parasites and not inhibitory to their growth, according 
to a procedure reported on a previous work.56 The compounds, at doses of 100, 50, 25, 10, l, 0.5, 0.25, 
and 0.1 μM were added to the culture medium. For each compound, the effects against T. cruzi 
epimastigote forms were assayed at 72 h with a hemocytometric chamber (Neubauer). The anti-
trypanosomatid effect is expressed as the IC50. That is, the concentration needed for 50% growth 
inhibition, determined by linear regression with the Kc values of the concentrations used. 
Amastigote Assays (Intracellular Forms). Vero cells grown as indicated above in RPMI medium 
(Gibco), were inoculated at 1 × 104 cells/well in 24-well microplates (Nunc) that had rounded coverslips 
and cultured 2 days. Then the Vero cells were infected for 24 h in vitro using metacyclic forms at a 10:1 
ratio. After the removal of non-phagocytic parasites by washing, the drugs (100, 50, 25, 10, 1, 0.5 0.25 
and 0.1 μM) were added. Vero cells were incubated with the drugs at 37°C for 72 h in 5% CO2. The 
activity of the drugs was evaluated based on the number of amastigotes in treated as well as untreated 
cultures, in preparations that were methanol-fixed and Giemsa-stained. The number of amastigotes was 
estimated analyzing 200 host cells in randomly taken microscopic fields. The anti trypanosomal effect 
was expressed as the IC50. 
In vitro genotoxicity screening 
Bacteria. S. typhimurium TA1535/pSK1002 was obtained from the German Collection for 
Microorganisms and Cell cultures (DSMZ). Chemicals. DMSO, dextrose, NaCl, ampicillin, o-
nitrophenol-β-D-galactopyranoside (ONPG), Na2CO3, Na2HPO4.2H2O, NaH2PO4.H2O, MgSO4.7H2O, 
KCl, β-mercaptoethanol and sodium dodecyl sulphate were obtained from Sigma-Aldrich; 
Bactotryptone was obtained from BD; and rat S9 mix (Mutazyme) was obtained from Moltox. 
Reagents preparation for SOS/umu test. TGA culture medium was prepared dissolving 10 g 
bactotryptone, 2 g dextrose and 5 g NaCl in 1 L of water and sterilizing during 30 minutes at 121 ºC. B-
buffer was prepared dissolving 20.18 g Na2HPO4.2H2O, 5.5 g NaH2PO4.H2O, 0.75 g KCl, 0.25 g 
  
 
MgSO4.7H2O, 1.0 g SDS, 2.7 mL β-mercaptoethanol in 1 L water adjusting pH value to 7. Stop reagent 
(Na2CO3 1 M) was prepared dissolving 106 g of Na2CO3 in 1 L water. Phosphate buffer (for ONPG 
dissolution) was prepared dissolving 1.086 g Na2HPO4.2H2O and 0.538 g NaH2PO4.H2O in 100 mL 
water and adjusting pH value to 7. ONPG solution was prepared dissolving 45 mg ONPG in 10 mL 
phosphate buffer.  
SOS/umu test. The SOS/umu test was carried out according to the method of Oda et al. (1985) and 
Reifferscheid et al. (1991), with some modifications.57, 58 The test strain S. typhimurium 
TA1535/pSK1002 was used. It was pre-incubated overnight in TGA medium with ampicillin (50 μg/mL) 
by shaking in an incubator at 37 °C in order to obtain exponentially growing bacteria. The test was 
performed in the absence and the presence of external metabolic activation system (rat S9 mix) in order 
to determine the possible genotoxic effects of any metabolite. In each test performed, negative and 
positive controls were included. DMSO was used as solvent control, and 4-nitroquinoline-N-oxide (4-
NQO) and 2-aminofluorene (2-AF) were used as positive controls with and without of S9 mix. 
Test procedure was as follows: firstly, each compound tested was dissolved in DMSO at 40 mg/mL 
and 11 serial ½ dilutions were prepared in a 96-well plate (plate A; final volume in each well was 10 
μL). Next, 70 μL of water were added to each well. In another two 96-well plates (plates B; one for the 
test with S9 and the other without S9), 10 μL S9 mix or 10 μL PBS, were added , respectively, followed 
by the addition of 25 μL of each previously prepared compound. Finally, 90 μL of exponentially 
growing bacteria was added and incubated during 4 hours by shaking at 37 ºC. After the incubation 
period, absorbance at 600 nm was measured in order to evaluate toxicity on S. typhimurium 
TA1535/pSK1002. Toxicity was calculated as follows: 
Survival percentage = (A600 for each concentration tested/media A600 for negative control)*100 
Afterwards, for the determination of β-galactosidase activity, in two new 96-well plates (plates C), 
150 μL of ONPG solution were added to each well and 30 μL of the contents of each well of plates B 
were transferred to these plates C. Both plates were incubated for 30 minutes by shaking at 28 ºC, 
avoiding direct light exposure. After the incubation period, 120 μL of stop reagent were added and the 
  
 
reaction was stopped. Absorbance (420 nm) was then measured immediately, and β-galactosidase 
activity (relative units; RU) was calculated as follows: 
β-galactosidase enzymatic units = A420 for each concentration tested/A600 for each concentration 
tested 
Finally, the induction factor (IF) was calculated as follows: 
IF = β-galactosidase RU for each concentration tested/media β-galactosidase RU for negative control, 
where: media β-galactosidase RU for negative control = media A420 for negative control/media A600 
for negative control 
In the same way, β-galactosidase relative units were calculated for both positive controls, and the test 
was only considered valid if the positive controls reached an induction factor ≥2 under the given test 
conditions. 
Thus, a compound was consider genotoxic, as it induces the induction of the umu operon, when in any 
of the conditions studied (with or without metabolic activation), the induction factor was ≥2 at non 
cytotoxic concentrations (bacteria survival percentage ≥80%), presenting a dose-response relationship. 
Wells in which compound precipitation was observed, were discarded from analysis. 
Infectivity Assay 
Vero cells were cultured under the same conditions for two days. The, cells were then infected in vitro 
with T. cruzi metacyclic forms, at a 10:1 ratio. Immediately after infection, the drugs (IC25 
concentrations) were added, followed by incubation at 37°C for 12 h in 5% CO2. After removal of the 
drugs and nonphagocytosed parasites by washing, the infected cultures were grown in fresh medium for 
10 day.41 Every 48 h, fresh culture medium was added. The activity of the drugs was determined from 
the % of infected cells, the number of amastigotes per infected cell, and the number of trypomastigotes 
in the medium, both in treated as well as untreated cultures, and in methanol-fixed as well as Giemsa-
stained preparations. A determination was made every 48 h of the mean number of amastigotes per 
infected cell and the % of infected cells by examining 200 host cells in randomly taken microscopic 
  
 
fields. The trypomastigotes in the medium were counted every 48 h in a hemocytometric chamber 
(Neubauer). 
In Vivo Trypanocidal Activity Assay 
For the following purposes, in the in vivo stage, experimental tests were performed: i) to assess the 
influence that the compounds exerted on the parasitemia levels post- treatment by a Neubauer chamber 
count for 40 days as an acute-phase marker; ii) to provide a measure of the parasitemia reactivation 
following immunosuppression as a chronic-phase marker; iii) to compare the levels of the chronic and 
acute phases of Ig-G using ELISA as an immune-response indicator; and iv) for detection of the 
parasite’s presence using PCR in target organs. 
Mice Infection and Treatment. The mice were handled following the international guide for 
biomedical research using experimental animals and the experiment was approved by the ethics board of 
the University of Granada (Spain). Groups of six female BALB/c albino mice 8 to 10 weeks old and 
weighing 25 to 30 g, were kept under standard conditions and given free access to standard chow and 
water.  The mice were infected intraperitoneally using 5 x 105 blood trypomastigotes (T. cruzi Arequipa 
strains) from the blood of mice previously infected. These animals were split in the three groups: I, 
untreated infected mice constituted the positive control group; II, infected mice treated using the 
reference drug made up the BZN group; and III, infected mice treated using the compounds under 
investigation comprised the study group. The tested compounds were administered beginning on the day 
7 after confirmation of the infection, and dosages of 50 and 100 mg/kg body mass per day were given 
orally on 5 alternating days (day 7 to 15  pi). In each mouse, peripheral blood was taken from the 
mandibular vein (5 μL samples) and this was diluted in 495 μL PBS solution (1:100). The circulating 
parasites were counted in a Neubauer chamber every 3 days for 40 d (acute phase). The number of 
bloodstream forms detected was expressed in parasites/mL. 
Immunosuppression Induced by Cyclophosphamide- and Cure Assessment. At day 90 pi, the groups in 
which the parasitemia levels had significantly fallen, (irrespective of the treatment the mice received) 
and could not be detected by microscopic examination of fresh blood, were subjected to 3 cycles of 
  
 
immunosuppression using CP (cyclophosphamide monohydrate ISOPAC®) as follows: 4 days 
consecutively on which the mice were given 1 intraperitoneal injection/day (dosage 200 mg/kg·w/day), 
and 3 days off. The effectiveness of this immunosuppression technique for evaluating cryptic infection 
was corroborated by the mortality rate of nearly 100% in chronically untreated mice and/or by the high 
parasitemia rate. The parasitemia was assessed within 1 week after the last injection of CP, following 
the procedure explained above for the acute phase in order to quantify the trypomastigote forms in blood 
as the reactivation rate. The mice were finally bled by heart puncture under gaseous anesthesia (CO2).  
Blood was incubated for 2 hours at 37 ºC and then over night at 4º C in order to allow clotting. 
Subsequently, the serum was obtained after centrifuging the supernatant twice at 1000 and 2700 g, 
consecutively. The serum was used for ELISA and biochemical analysis as explained further on in this 
paper. Thanks to our previous in vivo studies, we observed that the tropism of T. cruzi strain (Arequipa) 
occurs in the following organs: adipose, brain, heart, esophagus, stomach, bone marrow, muscle and 
lung. Therefore these 8 target organs were harvested and immediately flushed free of blood by gentle 
infusion of pre-warmed PBS for the purpose of avoid contamination of collected tissue with blood 
parasites. Next, they were used for DNA extraction, as explained below. In addition, spleens were 
weighed to evaluate inflammation of these organs in different groups of mice. 
ELISA Tests. Fe-SOD excreted from the parasite, cultured and processed as described by Lopez-
Céspedes et al.59 was used as antigen. Circulating antibodies in serum against T. cruzi, from day 40 to 
day 120 post-infection (including sera post-immunosuppression), were qualitatively and quantitatively 
assessed using ELISA. The serum was centrifuged from whole blood and diluted in PBS to 1:80. The 
absorbance was read at 492 nm using a microplate reader (Sunrise, TECAN). All samples, in triplicate, 
were analyzed in polystyrene microtiter plates. For calculating the cutoff value, the mean and standard 
deviations of the optical density of the negative control sera were used. 
PCR and DNA Extraction. The organs to be studied were thawed and then ground using a Potter-
Elvehjem for purification using Wizard® Genomic DNA Purification Kit (Promega). The PCR was 
conducted with two primers from our laboratory (unpublished data), based on the published SOD 
  
 
(superoxide dismutase) sequence of T. cruzi CL Brenner (GenBank accession No. XM_808937); this 
amplifies a fragment pertaining to T. cruzi SOD gene b of c. 300 pb. The amplification was performed 
in Thermal Cycler TM MyCycler thermocycler (BioRad). 
Studies of the action mechanism of  
Superoxide Dismutase (SOD) Inhibition Studies. T. cruzi epimastigotes cultured as indicated above 
were centrifuged and collected. After the suspension of the pellet in 3 mL of STE buffer (0.25 M 
sucrose, 25 mM Tris–HCl, 1 M EDTA, pH 7.8), the cells were broken up by ultrasonication (three 
cycles) at 60 W every 30 s. Following 1500-g centrifugation of the homogenate at 4ºC for 5 min and, 
the pellet was washed in ice-cold STE buffer three times and centrifuged (2500 g at 4ºC for 10 min)  
The supernatant was collected to determine its protein concentration using the Bradford method.60The 
activities of Fe-SOD and CuZn-SOD (iron and copper-zinc superoxide dismutases) (were determined by 
the method of Beyer and Fridovich,61 to measure the extent to which nitrobluetetrazolium (NBT) was 
reduced by superoxide ions. To each cuvette, the following was added: 1.5 mL of Triton X-100 1% 
(v/v)], 2 mL of NBT (1.41 mg, 10 mL−1), and 845 μL of stock solution [3 mL of L-methionine (300 mg, 
10 mL−l), as well as 30 μL of the homogenate fraction of the parasite, 10 μL riboflavin (0.44 mg, 10 
mL−l), and an equivalent volume of the compound solution. For each compound, 5  concentrations were 
used: 1 to 100 μM. For the control experiment, the volume was raised to 1000 μL using 50 mM 
potassium phosphate buffer (pH 7.8), while 30 μL of the homogenate fraction of the parasite were added 
to the mixtures that contained the compounds. A spectrophotometer was used to measure the absorbance 
(A0), at 560 nm. Each cuvette was placed under lamp light for 10 min with constant stirring, and a 
measurement was made of the absorbance (A1). The substrates, coenzymes, and human CuZn-SOD used 
in these tests were from Sigma Chemical Co. The data were submitted to the Newman–Keuls test.62 
Metabolite excretion. Cultures of epimastigotes of T. cruzi Arequipa strain at a starting concentration 
of 5×105 cells/mL) received the IC25 dosage of each compound (excepting control cultures). After 72 h 
of incubation for at 28°C the cells underwent centrifugation (400 g) for 10 min. After supernatant 
collection, the excreted metabolites were determined by 1H NMR; using sodium 2,2-dimethyl-2-
  
 
silapentane-5-sulphonate as the reference signal, and chemical shifts were expressed in ppm. The 
chemical shifts used for the identification of the respective metabolites were in line with those that some 
of the co-authors have reported previously.62 
Mutagenicity studies 
Bacteria. S. typhimurium histidine auxotrophic strains TA 98, TA 100, TA 102, TA 1535 and TA 
1537 were obtained from Moltox (Trinova, Biochem GmbH). Chemicals. S9 mix (Mutazyme) was 
obtained from Moltox. All the reagents were obtained from Sigma-Aldrich. 
Bacterial reverse mutation test (Ames test). 
The bacterial reverse mutation test, so-called the Ames test, was performed following the 
recommendations of the OECD guideline 471 and using the pre-incubation version. 63 Bacteria were 
exposed to 5 soluble and non-toxic concentrations of the test compound in absence or presence of an 
external enzymatic metabolizing system (S9 Mix). Briefly, 100 µL of bacterial suspension were mixed 
with 50 µL of each test compound solution and 500 µL of PBS or S9 mix. After 1 h of incubation at 37 
ºC, 2 mL of molten top agar supplemented with histidine and biotin traces (i.e. 0.05 mM each) were 
added to the mix, vortexed, and poured onto glucose minimal agar plates. Plates where then incubated 
for 48 h at 37 ºC before histidine revertants colonies were counted. For-nitro-o-phenylendiamine (NPD) 
and sodium azide (NaAZ) were used as positive controls in the absence of S9 mix, while 2-
aminoantracene (2-AA) and 2-aminofluorene (2-AF) were used in the presence of S9 mix. DMSO was 
used as negative control. Experiments were performed using technical triplicates. 
Docking study 
The compounds were designed with the program Ghemical,64 using the protonation state at pH 7.4 
determined by the chemicalize web server (http://www.chemicalize.org/). For the enzymes, the PDB 
structures with codes 4DVH and 2GPC were used for the mitochondrial and cytosolic T. cruzi Fe-SOD 
proteins, respectively; and the PDB structure with code 2C9V was used for the human CuZn-SOD. 
Their protonation states at pH 7.4 were obtained with the program PDB2PQR.65 Afterwards, Gasteiger 
charges for both proteins and ligand were added with Autodock.66 The docking study was performed 
  
 
with the Autodock4.0 program, using the Lamarckian genetic algorithm (LGA).67 In a first step, a grid 
was defined containing the whole protein. After the binding site was determined, docking runs 
generating 100 poses were carried out for each protein/ligand, using a smaller grid center on the binding 
site. 
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Table 1. Proposed TPP for Chagas disease modified from DNDi11  
TPP Acceptable Ideal 
Target population Chronic Chronic and acute 
Adult/children Adult All 
Clinical efficacy Superiority to BZN in all endemic 
regions 
Superiority to BZN to different 
phases of disease (acute and 
chronic; reactivated patients) 
Active against resistant 
strains 
Not necessary Active against nitrofuran- and 
nitroimidazole-resistant T. cruzi 
strains 
Safety Superiority to BZN Superior to BZN 
Contraindications Pregnancy/lactation None 
Precautions No genotoxicity 








Presentation Oral Oral 
Dosing regime Comparable to systemic antifungal 
treatments 
Once daily for 30 days 
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Table 3. Molecular properties of the new compounds calculated with the DataWarrior program.22 
Comp. MWa clogPb clogSc PSAd HBAe HBDf 
1 371.3 3.2 -5.1 51.8 3 0 
2 356.4 3.1 -5.1 51.8 3 0 
3 362.4 4.1 -4.8 97.6 6 0 
4 437.4 3.6 -5.4 51.8 3 0 
5 404.9 3.5 -5.4 51.8 3 0 
6 372.8 3.6 -5.1 97.6 6 0 
7 455.4 3.7 -5.0 51.8 3 0 
8 383.4 1.1 -3.8 51.8 3 0 
9 384.9 4.3 -4.1 51.8 3 0 
10 386. 5 3.9 -6.3 106.4 6 1 
11 389.4 2.2 -3.8 51.8 3 0 
12 429.4 4.0 -3.7 51.8 3 0 
13 395.5 1.8 -4.7 61.0 4 0 
14 402.9 4. 4 -5.5 23.5 3 0 
15 406.4 3.8 -5.2 69.4 6 0 
16 412.4 4.9 -5.0 23.5 3 0 
17 413.5 1.9 -4.6 42.0 5 0 
18 454.9 4.5 -4.5 42.0 5 0 
19 436.5 4.6 -4.3 87.8 8 0 
20 463.5 2.0 -4.1 42.0 5 0 
aTotal Molecular Weight (g/mol). bLogarithm of the partition coefficient between n-octanol and water. 
cLogarithm of the solubility measured in mol/L. dPolar Surface Area (Å2). eNumber of hydrogen-bond 
acceptors. fNumber of hydrogen-bond donors. 
  
 
Table 4. In vitro activity and toxicity for the 20 arylaminoketone derivatives on extra- and intracellular forms of 
Trypanosoma cruzi strains. 
Comp. 
 
Activity IC50 (µM)a 
T. cruzi Arequipa strain 
Activity IC50 (µM)a 
T. cruzi Tulahuen strain 
Activity IC50 (µM)a 
T. cruzi SN3 strain 
bVero cells 
toxicity  



















BZN 15.8±1.1 23.7±4.6 12.6±1.3 18.7±1.1 21.7±4.6 12.8±0.7 15.8±1.1 23.3±4.6 6.2±0.7 13.6±0.9 
1 21.9±1.3 19.3±1.4 32.3±1.5 48.2±4.0 8.1±0.7 6.6±0.3 40.6±3.6 21.4±1.7 43.2±3.5 236.9±12.6 
2 30.6±2.0 25.3±1.8 31.4±1.3 42.3±3.6 10.1±0.3 12.8±0.9 23.6±1.4 26.3±1.9 43.2±4.0 157.2±6.8 
3 77.7±3.1 11.7±1.8 35.9±2.5 35.5±2.8 19.8±1.3 0.5±0.1 41.4±3.5 20.7±0.9 18.6±2.1 1710.4±69.8 
4 51.7±6.8 27.9±4.7 13.9±0.6 14.0±0.9 25.8±2.1 45.8±3.5 10.1±0.6 8.7±0.7 6.6±1.1 896.0±45.7 
5 28.5±0.8 13.2±2.5 9.6±0.4 9.6±0.4 14.8±0.8 21.8±1.5 30.1±1.3 17.6±1.5 19.6±1.3 245.7±12.5 
6 36.6±2.5 19.8±1.9 43.3±2.5 48.1±3.7 8.8±0.8 52.4±2.3 39.4±1.2 16.3±1.2 4.1±0.3 553.7±14.3 
7 30.7±1.1 12.7±2.1 0.3±0.2 0.4±0.0 4.9±1.0 1.9±0.5 12.3±1.0 7.9±0.6 5.1±0.3 758.6±59.7 
8 29.7±2.3 31.7±2.6 43.3±2.5 30.1±1.3 21.7±1.6 32.3±2.9 42.5±3.3 18.7±1.4 20.8±1.3 129.8±8.8 
9 86.7±4.6 22.6±1.3 39.5± 3.1 28.9±1.3 20.±1.2 27.3±1.2 53.9±3.6 32.0±2.0 86.3±5.1 70.8±4.6 
10 26.0±0.8 10.8±0.9 20.3±1.8 50.3±3.7 22.8±1.3 2,5±0.6 179.2±6.7 72.9±2.3 33±2.5 2846.3±123.8 
11 28.0±1.7 18.6±1.7 26.8±1.9 28.0±1.7 20.2±0.9 22.3±1.4 12.8±0.6 5.7±0.3 4.6±0.2 4.8±0.9 
12 14.1±0.8 10.0±0.4 46.9±3.6 28.0±2.0 7.7±0.3 22.3±0.7 24.1±1.6 16.3±0.6 21.8±1.5 65.8±1.8 
13 2.5±0.3 0.8±0.1 0.7±0.01 4.7±0.3 2.0±1.0 2.3±1.0 21.2±1.1 24.2±1.6 37.5±2.2 137.9±6.6 
14 1.23±0.2 2.6±1.4 8.3±2.1 4.2±0.1 20.5±1.2 6.6±1.2 15.3±1.3 8.3±0.4 36.5±2.2 30.1±2.6 
15 3.4±0.7 5.4±1.3 3.9±0.6 6.9±0.5 8.6±0.7 6.9±1.7 27.7±1.6 20.3±1.8 26.4±1.2 74.3±5.3 
16 49.0±4.1 23.9±1.6 24.6±1.3 27.6±1.6 20.3±1.7 25.5±0.9 24.1±0.6 12.4±0.8 10.7±1.1 102.8±4.7 
17 50.6±2.8 27.9±2.6 21.8±1.5 21.8±1.3 17.6±1.6 23.7±3.2 17.8±0.8 13.0±1.1 14.2±0.8 48.7±3.5 
18 2.5±1.0 1.7±0.4 46.3±4.3 69.1±4.9 11.2±0.7 29.3±1.8 12.6±0.7 6.2±0.7 16.8±1.3 0.3±0.0 
19 1.4±0.5 1.2±0.2 0.58±0.1 15.6±2.0 11.6±0.7 0.08±0.0 18.8±1.4 11.4±0.8 50.9±2.3 275.8±17.2 
20 97.0±6.3 22.4±1.2 34.6±2.6 199.5±13.1 22.3±1.4 56.3±3.1 17.6±1.2 14.8±0.8 63.4±4.2 322.8±30.1 
Results are averages of four separate determinations. a IC50: is the concentration required to give 50% 
inhibition, calculated by linear regression analysis from the Kc values at the concentrations employed (1 to 




Table 5. Selectivity index and in vitro toxicity for the 20 derivatives of arylaminoketone intra and extracellular 
of T .cruzi strains. 
Comp. 
Selective Indexc 
T. cruzi Arequipa strain 
Selective Indexc 
T. cruzi Tulahuen  strain 
Selective Indexc 
T. cruzi SN3  strain 
Vero cells 
toxicity  



















BZN 0.9 0.6 0.9 0.8 0.6 1.1 1.2 0.6 0.5 13.6±0.9 
1 11 (12) 12 (20) 7 (8) 5 (6) 29 (49) 36 (33) 6 (5) 11 (18) 6 (11) 236.9±12.6 
2 5 (6) 6 (10) 5 (6) 4 (5) 16 (26) 12 (10) 7 (6) 6 (10) 4 (7) 157.2±6.8 
3 22 (25) 146 (244) 48 (53) 48 (60) 86 (144) 3420 (3109) 41 (34) 83 (138) 92 (184) 1710.4±69.8 
4 17 (19) 32 (53) 864 (72) 64 (80) 35 (58) 20 (19) 89 (74) 103 (172) 136 (271) 896.0±45.7 
5 9 (10) 19 (31) 26 (28) 26 (32) 17 (28) 11 (10) 8 (7) 14 (23) 12 (25) 245.7±12.5 
6 15 (17) 28 (35) 13 (14) 11 (19) 63 (105) 11 (10) 14 (12) 34 (57) 135 (270) 553.7±14.3 
7 25 (27) 60 (99) 2528 (2810) 1896 (3160) 155 (258) 399 (333) 62 (51) 96 (160) 149 (299) 758.6±59.7 
8 4 (5) 4 (7) 3 (3) 4 (5) 6 (10) 4 (4) 3 (2) 7 (12) 6 (12) 129.8±8.8 
9 1 (1) 3 (5) 2 (3) 2 (3) 3 (6) 3 (2) 1 (1) 2 (4) 1 (1.6) 70.8±4.6 
10 109 (122) 263 (439) 140 (156) 57 (78) 125 (208) 1138 (1035) 16 (14) 39 (65) 87 (172) 2846.3±123.8 
11 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 1 (2) 4.8±0.9 
12 5 (5) 7 (11) 1 (2) 2 (3) 8 (14) 3 (3) 3 (2) 4 (7) 3 (6) 65.8±1.8 
13 55 (61) 172 (287) 197 (219) 30 (37) 69 (115) 60 (55) 6 (5) 6 (9) 4 (7) 137.9±6.6 
14 24 (27) 12 (19) 4 (4) 7 (8) 1 (2) 5 (4) 2 (2) 4 (6) 1 (2) 30.1±2.6 
15 22 (24) 14 (23) 19 (21) 11 (13) 9 (14) 11 (10) 3 (2) 4 (6) 3 (6) 74.3±5.3 
16 2 (2) 4 (7) 4 (5) 4 (5) 5 (8) 4 (4) 4  (4) 8 (14) 10 (19) 102.8±4.7 
17 1 (1) 2 (3) 2 (2) 2 (3) 3 (5) 2 (2) 3 (2) 4 (6) 3 (7) 48.7±3.5 
18 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0.3±0.0 
19 197 (219) 230 (383) 552 (528) 18 (22) 16 (26) 3447 (3134)                                       15 (12) 24 (40) 5 (11) 275.8±17.2 
20 3 (4) 14 (24) 9 (10) 2 (2) 14 (24) 6 (5) 18 (15) 22 (36) 5 (10) 322.8±30.1 
c Selectivity index =IC50 Vero cells toxicity/IC50 activity on extracellular or intracellular forms of the parasite. 
In brackets: number of times the compound SI exceeded the reference drug SI. 
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Table 6. Weight percent of spleens of different groups of mice. 
Treatment (50 mg) Weight percent Treatment (100 mg) Weight percent 
Control (untreated) 1.603 Control (untreated) 1.603 
3 1.174 BZN 0.837 
4 1.621 3 0.729 
7 1.061 4 1.041 
10 1.171 7 0.825 
  10 0.892 
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Table 7. Results of the Ames test of compound 4. 
Treatment 
Preincubation assay 
Mean number of revertant colonies per plate 
TA98 TA100 TA102 TA1535 TA1537 
-S9 +S9 -S9 +S9 -S9 +S9 -S9 +S9 -S9 +S9 
Negative control 12±4 12±0 114±24 119±6 413±80 420±130 10±1 8±3 2±2 4±1 
Test dose (µg/plate)           
0.03 15±1 12±1 90±20 128±8 532±69 550±65 13±2 11±2 2±1 2±1 
0.08 16±3 15±2 100±3 131±18 484±61 504±25 13±3 11±5 3±2 4±3 
0.25 14±2 10±5 107±13 120±16 459±28 553±85 11±4 16±2 4±3 4±2 
0.75 16±1 12±2 109±13 136±4 473±42 546±63 13±4 8±1 2±1 2±1 
2.25 14±2 11±3 110±12 139±4 487±29 540±76 9±1 12±3 4±3 2±2 
Positive control 1608±352 1250±85 704±9 1900±164 739±36 1142±148 151±8 239±69 791±32 243±18 
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Table 8. Results of the Ames test of compound 7. 
Treatment 
Preincubation assay 
Mean number of revertant colonies per plate 
TA98 TA100 TA102 TA1535 TA1537 
-S9 +S9 -S9 +S9 -S9 +S9 -S9 +S9 -S9 +S9 
Negative control 16±3 27±4 134±6 135±20 483±279 363±27 16±1 14±3 6±3 9±1 
Test dose (µg/plate)           
0.01 23±5 23±4 138±3 161±3 423±58 319±45 18±4 13±2 9±2 13±5 
0.03 17±1 30±7 140±4 154±8 365±22 298±23 12±4 17±2 4±0 6±1 
0.08 21±13 25±1 138±11 175±9 378±28 265±6 14±5 16±2 7±2 10±2 
0.25 19±4 24±6 134±4 164±19 363±54 313±20 11±4 15±5 4±4 8±2 
0.75 15±6 28±5 128±9 153±27 356±44 263±19 12±2 15±8 6±2 6±4 
Positive control 962±131 890±76 595±35 1078±79 491±41 486±33 423±53 112±3 79±2 21±4 
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Figure 1. General method of synthesis of new arylaminoketone derivatives. 
 i: corresponding amine, 1,3-dioxolane, H+, reflux. 
Figure 2. Reduction of the infection of Trypanosoma cruzi in Vero cells treated with (-■-) BZN, 
(-Δ-) 3, (-□-) 4, (-●-) 7 and (-▲-) 10. (A) Rate of infection; (B) mean number of amastigotes per 
infected Vero cells; (C) number of trypomastigotes in the culture medium. Measured at IC25. 
Values are the means of the three separate experiments. 
Figure 3. Parasitemia in mice with acute CD. In (-♦-) control, (-▲-) BZN, (-●-) compound 3, (-
■-) compound 4, (-Δ-) compound 7 and (-□-) compound 10. In all cases, compounds were orally 
administered using, for each compound, 100 mg/kg of body mass. Values constitute means of six 
mice ± standard deviation. Treatment days are represented in grey. 
Figure 4. Immunosuppression in vivo assay for mice untreated and treated with 100 mg/kg of 
body mass of BZN, 3, 4, 7 and 10. Figure shows the reactivation of blood parasitemia after the 
immunosuppression cycles by fresh blood containing to the peak day parasitemia during acute 
phase. 
Figure 5. Shows differences in the IgG levels measured by ELISA at different day post-
infection. 
Figure 6. Polymerase chain reaction (PCR) analysis of the 8 target organs on day 120 after 
infection. Lanes: M, base pair marker; 1: PCR negative control; 2: PCR positive  control; 3: PCR 
adipose tissue; 4: PCR brain tissue; 5: PCR heart tissue; 6: PCR esophagus tissue; 7: PCR 
stomach tissue; 8: PCR bone marrow tissue; 9: PCR muscle tissue; 10: PCR lung tissue. * This 
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means that 1/6 of the corresponding organ PCR products showed 300 bp band on 
electrophoresis. 
Figure 7. A) Inhibition in vitro (%) of Fe-SOD from epimastigotes of Trypanosoma cruzi for 
compounds (activity 25.4 ± 3.1 U/mg). B) Inhibition in vitro (%) of CuZn-SOD from human 
erythrocytes for compounds (activity 23.36± 2.5 U/mg). Activity differences in the control 
homogenate vs. the sample incubated using compounds were identified by the Newman-Keuls 
test. Values are the average of three separate rate determinations. 
Figure 8. Percentages of variation among peaks of catabolites excreted by epimastigotes of  
Trypanosoma cruzi exposed to compounds 3, 4, 7 and 10 at their IC25 in comparison to a control 
incubated 96 h. 
Figure 9. Docking results for the binding of benzothiophenes derivatives 3 (up-left), 4 (down-
left), 7 (up-right) and 10 (down-right) to the Trypanosoma cruzi Fe-SOD (a) and the human 
CuZn-SOD (b) enzymes. In the center, an image of the entire enzyme with the compounds 
binding at the top of the dimer interface is shown. Residues forming the inhibitor binding site are 
shown. Color scheme: oxygen (red), nitrogen (blue), sulfur (yellow), carbon (pale pink for 
compound 3, orange for compound 4, blue for compound 7 and magenta for compound 10. For 
the proteins, one monomer is shown in green and the other in yellow). The ions are shown as 
spheres. Figures were created with The PyMOL Molecular Graphics System, Version 1.8 
Schrödinger, LLC. 
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Figure 1. General method of synthesis of new arylaminoketone derivatives. 
 i: corresponding amine, 1,3-dioxolane, H+, reflux. 
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Figure 2. Reduction of the infection of Trypanosoma cruzi in Vero cells treated with (-■-) BZN, 
(-Δ-) 3, (-□-) 4, (-●-) 7 and (-▲-) 10. (A) Rate of infection; (B) mean number of amastigotes per 
infected Vero cells; (C) number of trypomastigotes in the culture medium. Measured at 
IC25.Values are the means of the three separate experiments. 
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Figure 3. Parasitemia in mice with acute CD. In (-♦-) control, (-▲-) BZN, (-●-) compound 3, (-
■-) compound 4, (-Δ-) compound 7 and (-□-) compound 10. In all cases, compounds were orally 
administered using, for each compound, 100 mg/kg of body mass. Values constitute means of six 
mice ± standard deviation. Treatment days are represented in grey.  
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Figure 4. Immunosuppression in vivo assay for mice untreated and treated with 100 mg/kg of 
body mass of BZN, 3, 4, 7 and 10. Figure shows the reactivation of blood parasitemia after the 
immunosuppression cycles by fresh blood containing to the peak day parasitemia during acute 
phase. 
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Figure 5. Shows differences in the IgG levels measured by ELISA at different day post-
infection. 
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Figure 6. Polymerase chain reaction (PCR) analysis of the 8 target organs on day 120 after 
infection. Lanes: M, base pair marker; 1: PCR negative control; 2: PCR positive control; 3: PCR 
adipose tissue; 4: PCR brain tissue; 5: PCR heart tissue; 6: PCR esophagus tissue; 7: PCR 
stomach tissue; 8: PCR bone marrow tissue; 9: PCR muscle tissue; 10: PCR lung tissue. * This 
means that 1/6 of the corresponding organ PCR products showed 300 bp band on 
electrophoresis.  
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Figure 7. A) Inhibition in vitro (%) of Fe-SOD from epimastigotes of Trypanosoma cruzi for 
compounds (activity 25.4 ± 3.1 U/mg). B) Inhibition in vitro (%) of CuZn-SOD from human 
erythrocytes for compounds (activity 23.36± 2.5 U/mg). Activity differences in the control 
homogenate vs. the sample incubated using compounds were identified by the Newman-Keuls 
test. Values are the average of three separate rate determinations. 
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Figure 8. Percentages of variation among peaks of catabolites excreted by epimastigotes of  
Trypanosoma cruzi exposed to compounds 3, 4, 7 and 10 at their IC25 in comparison to a control 
incubated 96 h. 
  
  60 
 
 
  61 
Figure 9. Docking results for the binding of benzothiophenes derivatives 3 (up-left), 4 (down-
left), 7 (up-right) and 10 (down-right) to the Trypanosoma cruzi Fe-SOD (a) and the human 
CuZn-SOD (b) enzymes. In the center, an image of the entire enzyme with the compounds 
binding at the top of the dimer interface is shown. Residues forming the inhibitor binding site are 
shown. Color scheme: oxygen (red), nitrogen (blue), sulfur (yellow), carbon (pale pink for 
compound 3, orange for compound 4, blue for compound 7 and magenta for compound 10. For 
the proteins, one monomer is shown in green and the other in yellow). The ions are shown as 
spheres. Figures were created with The PyMOL Molecular Graphics System, Version 1.8 
Schrödinger, LLC. 
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